Skip Navigation
Menu

朴炯秀(パク・ヒョンス) 外国弁護士

パク・ヒョンス 外国弁護士
パク・ヒョンス 外国弁護士

朴炯秀(パク・ヒョンス)外国弁護士

T.+82-2-6488-4186F.+82-2-2122-3800E.hyeongsu.park@kimchang.com

関連分野

紹介

Hyeongsu Park advises clients on patent prosecution, patent licensing, opinion work, IP due diligence, patent strategies and litigation. With his background in biomedical engineering and molecular biology, he assists various clients including those in pharmaceutical, medical device and biotech industries.

Mr. Park received his J.D. from Harvard Law School. While in law school, he served as an editor and member of the Submissions Committee for the Harvard Journal of Law & Technology. He was also a student intern at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

Prior to his legal education, Mr. Park earned his Bachelor's degree in Biological Engineering from Cornell University. He conducted research on a RNA-guided genome engineering (CRISPR/Cas9) system and a DNA-based drug delivery system.

プロフィール

経歴

KIM & CHANG (2018, 2021~ ) 

Researcher, Bioinfra Life Science, Inc. (2018-2021) 

Knobbe, Martens, Olson & Bear LLP (2015-2017)

主な活動View All

著書/活動
    • Patent-Eligible Subject Matter (South Korea), Practical Law Global, Thomson Reuters (Co-author, 2023)
    • Inventive Step Standard of Korean Patent Law in Relation to Pharmaceutical Invention, 17(3) L. & Tech. 50 (2021)
    • Determining Punitive Damages for Patent Infringement - Intentional Infringement and Statutory Factors Affecting Punitive Damages, 16(2) L. & Tech. 87 (2020) 
    • Artificial Intelligence and Patent-Eligible Subject Matter Under Korean Patent Law, 15(5) L. & Tech. 18 (2019) 
    • The Legal Battle Around CRISPR Gene-Editing Technology and Its Implications, 36 Biotech. L. Rep. 39 (2017) 
    • What SCOTUS's Refusal To Review Cases on Patent-Eligible Subject Means, MedCity News (January 2017) 
    • Ten Strategies for Aggressively Building a Patent Portfolio, Medical Device and Diagnostics Industry (MD+DI) (November 2016) 
    • The Defend Trade Secrets Act's Implications for Medtech, Medical Device and Diagnostic Industry (MD+DI) (June 2016) 
    • Draft Guideline for the Revised De Novo Classification Process, Harv. J.L. & Tech. Dig. (June 2016) 
    • Taxpayer Data Disclosure for Academic Use in South Korea, 79 Tax Notes Int'l 955 (2015) (Co-authored with Yunjung Song) 
    • Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott, Harv. J.L. & Tech. Dig. (March 2014)

学歴

Graduate School of Law, Seoul National University (Completed Coursework, LL.D., 2021) 

Harvard Law School (J.D., 2015) 

Graduate School of Arts and Sciences, Harvard University (Ph.D. Candidate, Molecular Biology, 2013-2014)

Cornell University (B.S., Biological Engineering, summa cum laude, Banner Bearer, 2010)

資格

Admitted to bar, California, 2016 

Admitted to patent bar (limited recognition), U.S. Patent and Trademark Office, 2016

言語

英語, 韓国語

関連分野

Close

業務分野

Close

共有する

Close
  

朴炯秀(パク・ヒョンス)
外国弁護士


T. +82-2-6488-4186      
F. +82-2-2122-3800
     


  




Hyeongsu Park advises clients on patent prosecution, patent licensing, opinion work, IP due diligence, patent strategies and litigation. With his background in biomedical engineering and molecular biology, he assists various clients including those in pharmaceutical, medical device and biotech industries.

Mr. Park received his J.D. from Harvard Law School. While in law school, he served as an editor and member of the Submissions Committee for the Harvard Journal of Law & Technology. He was also a student intern at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.

Prior to his legal education, Mr. Park earned his Bachelor's degree in Biological Engineering from Cornell University. He conducted research on a RNA-guided genome engineering (CRISPR/Cas9) system and a DNA-based drug delivery system.






    KIM & CHANG (2018, 2021~ ) 

    Researcher, Bioinfra Life Science, Inc. (2018-2021) 

    Knobbe, Martens, Olson & Bear LLP (2015-2017)






著書/活動

  •   Patent-Eligible Subject Matter (South Korea), Practical Law Global, Thomson Reuters (Co-author, 2023)
  •   Inventive Step Standard of Korean Patent Law in Relation to Pharmaceutical Invention, 17(3) L. & Tech. 50 (2021)
  •   Determining Punitive Damages for Patent Infringement - Intentional Infringement and Statutory Factors Affecting Punitive Damages, 16(2) L. & Tech. 87 (2020) 
  •   Artificial Intelligence and Patent-Eligible Subject Matter Under Korean Patent Law, 15(5) L. & Tech. 18 (2019) 
  •   The Legal Battle Around CRISPR Gene-Editing Technology and Its Implications, 36 Biotech. L. Rep. 39 (2017) 
  •   What SCOTUS's Refusal To Review Cases on Patent-Eligible Subject Means, MedCity News (January 2017) 
  •   Ten Strategies for Aggressively Building a Patent Portfolio, Medical Device and Diagnostics Industry (MD+DI) (November 2016) 
  •   The Defend Trade Secrets Act's Implications for Medtech, Medical Device and Diagnostic Industry (MD+DI) (June 2016) 
  •   Draft Guideline for the Revised De Novo Classification Process, Harv. J.L. & Tech. Dig. (June 2016) 
  •   Taxpayer Data Disclosure for Academic Use in South Korea, 79 Tax Notes Int'l 955 (2015) (Co-authored with Yunjung Song) 
  •   Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott, Harv. J.L. & Tech. Dig. (March 2014)





学歴

    Graduate School of Law, Seoul National University (Completed Coursework, LL.D., 2021) 

    Harvard Law School (J.D., 2015) 

    Graduate School of Arts and Sciences, Harvard University (Ph.D. Candidate, Molecular Biology, 2013-2014)

    Cornell University (B.S., Biological Engineering, summa cum laude, Banner Bearer, 2010)


資格

    Admitted to bar, California, 2016 

    Admitted to patent bar (limited recognition), U.S. Patent and Trademark Office, 2016


言語
  •    英語, 韓国語





特許・実用新案 ,  企業合併・買収 ,  IPデューデリジェンス、ライセンシング・取引 ,  製薬·医療機器·食品·化粧品 ,  バイオ及び生命工学 ,  放送・通信 ,  プライバシー・情報保護 ,  IPカウンセリング、ポートフォリオ管理&戦略 ,  知的財産権紛争